The Latin America, Middle East and Africa Antibiotics Market is expected to witness market growth of 6.2% CAGR during the forecast period (2020-2026).
Antibiotics are basically a combination of medicines that helps in curing infection caused by germs, bacteria, and some parasites. It kills all the infection-causing microorganisms. From the beginning of infectious diseases, till now, there have been numerous incidents of chronic and infectious diseases that are leading the growth of the antibiotic market. The growing prevalence of infectious diseases provides great opportunities for the companies, as antibiotics help in curing these infectious diseases. Therefore, it further accelerates the growth of the market.
The increasing incidents of chronic and infectious diseases around the globe and the properties of antibiotics to treat the broad spectrum of bacterial infections will propel the growth of the antibiotic market. There are many companies that are implementing some strategic plans of collaborative development programs to cut down their expenses. These plans will help the companies to develop more molecules. Further, the public-private collaborations, where funds and unique R&D approaches are adopted by public bodies and antibiotics manufacturers, will assist the creation of the latest and modern pipeline products.
The collaborative development efforts help the companies to widen up their range of products. It also encourages them to develop innovative and advanced solutions, which further support the growth of the antibiotic market.
Based on Action Mechanism, the market is segmented into Cell Wall Synthesis Inhibitors, Protein Synthesis Inhibitors, DNA Synthesis Inhibitors, RNA Synthesis Inhibitors, and Mycolic Acid Inhibitors. Based on Drug Class, the market is segmented into Cephalosporin, Penicillin, Fluoroquinolone, Macrolides, Carbapenem, Aminoglycosides, Sulfonamides, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include GlaxoSmithKline PLC (GSK), Johnson and Johnson, Merck & Co., Inc., Pfizer, Inc., Bayer AG, Novartis AG, Sanofi S.A., Abbott Laboratories, F. Hoffmann-La Roche Ltd., and Eli Lilly and Company.
Scope of the Study
Market Segments covered in the Report:
By Action Mechanism
By Drug Class
By Country
Companies Profiled
Unique Offerings from the Publisher
Antibiotics are basically a combination of medicines that helps in curing infection caused by germs, bacteria, and some parasites. It kills all the infection-causing microorganisms. From the beginning of infectious diseases, till now, there have been numerous incidents of chronic and infectious diseases that are leading the growth of the antibiotic market. The growing prevalence of infectious diseases provides great opportunities for the companies, as antibiotics help in curing these infectious diseases. Therefore, it further accelerates the growth of the market.
The increasing incidents of chronic and infectious diseases around the globe and the properties of antibiotics to treat the broad spectrum of bacterial infections will propel the growth of the antibiotic market. There are many companies that are implementing some strategic plans of collaborative development programs to cut down their expenses. These plans will help the companies to develop more molecules. Further, the public-private collaborations, where funds and unique R&D approaches are adopted by public bodies and antibiotics manufacturers, will assist the creation of the latest and modern pipeline products.
The collaborative development efforts help the companies to widen up their range of products. It also encourages them to develop innovative and advanced solutions, which further support the growth of the antibiotic market.
Based on Action Mechanism, the market is segmented into Cell Wall Synthesis Inhibitors, Protein Synthesis Inhibitors, DNA Synthesis Inhibitors, RNA Synthesis Inhibitors, and Mycolic Acid Inhibitors. Based on Drug Class, the market is segmented into Cephalosporin, Penicillin, Fluoroquinolone, Macrolides, Carbapenem, Aminoglycosides, Sulfonamides, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include GlaxoSmithKline PLC (GSK), Johnson and Johnson, Merck & Co., Inc., Pfizer, Inc., Bayer AG, Novartis AG, Sanofi S.A., Abbott Laboratories, F. Hoffmann-La Roche Ltd., and Eli Lilly and Company.
Scope of the Study
Market Segments covered in the Report:
By Action Mechanism
- Cell Wall Synthesis Inhibitors
- Protein Synthesis Inhibitors
- DNA Synthesis Inhibitors
- RNA Synthesis Inhibitors,
- Mycolic Acid Inhibitors
By Drug Class
- Cephalosporin
- Penicillin
- Fluoroquinolone
- Macrolides
- Carbapenem
- Aminoglycosides
- Sulfonamides,
- Others
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Companies Profiled
- GlaxoSmithKline PLC (GSK)
- Johnson and Johnson
- Merck & Co., Inc.
- Pfizer, Inc.
- Bayer AG
- Novartis AG
- Sanofi S.A.
- Abbott Laboratories
- F. Hoffmann-La Roche Ltd.
- Eli Lilly and Company
Unique Offerings from the Publisher
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Competition Analysis - Global
Chapter 4. LAMEA Antibiotics Market by Action Mechanism
Chapter 5. LAMEA Antibiotics Market by Drug Class
Chapter 6. LAMEA Antibiotics Market by Country
Chapter 7. Company Profiles
Companies Mentioned
- GlaxoSmithKline PLC (GSK)
- Johnson and Johnson
- Merck & Co., Inc.
- Pfizer, Inc.
- Bayer AG
- Novartis AG
- Sanofi S.A.
- Abbott Laboratories
- F. Hoffmann-La Roche Ltd.
- Eli Lilly and Company
Methodology
LOADING...
